The firm expects mid-single-digit price erosion in generic drugs and heightened competition for key medications, potentially ...

Healthcare stocks see mixed performance as Dr Lal Pathlabs and Aurobindo Pharma rise over 2% after CLSA upgrades their ...

CLSA analysts downgraded Dr. Reddy's Laboratories shares, trading on both BSE (DRRD:IN) and NYSE (NYSE:RDY), from a Hold to an Underperform rating, adjusting the price target from INR1,140 to INR1,090 ...

CLSA analysts downgraded Dr. Reddy's Laboratories shares, trading on both BSE (DRRD:IN) and NYSE (NYSE:RDY), from a Hold to an Underperform rating, adjusting the price target from INR1,140 to INR1,090 ...

This steady growth in HDFC Bank's core earnings - both NII and net profit - came in despite a marginal rise in NPAs and NPA ...

CLSA has initiated coverage on Hyundai Motor India with an 'Outperform' rating and a target price of Rs 2,155, citing strong ...

The brokerage firm has also added Zomato to its high conviction outperform list, saying the recent correction is a buying ...

CLSA has replaced HDFC Bank and added Tata Motors, NTPC, Nestle and Britannia in its portfolio. Here is everything you need to know on why CLSA is Overweight staples along with commodities.

This is the first time Indus Towers has received a ₹575 target, making it the highest among analysts covering the telecom ...

India's most valued company, Reliance Industries Ltd (RIL), reported a robust performance in the third quarter of the current ...

SK Hynix reports record Q4 earnings, driven by strong AI memory chip sales. Outlook for 2025 dims amid inventory adjustments ...